Skip to content

    Breast Cancer Health Center

    Font Size

    Drug Duo May Rapidly Shrink Breast Tumors in Some

    Researchers say combo therapy worked well for about 1 in 4 women with HER2-positive breast cancer

    WebMD News from HealthDay

    By Steven Reinberg

    HealthDay Reporter

    THURSDAY, March 10, 2016 (HealthDay News) -- A two-drug combo quickly shrinks certain breast cancer tumors before surgery or chemotherapy in some women, British researchers report.

    The specific breast cancer is called human epidermal growth factor receptor 2 (HER2) positive. The drug combination -- lapatinib (Tykerb) and trastuzumab (Herceptin) -- shrank HER2-positive tumors significantly in less than two weeks after diagnosis, the study authors said. In some cases, evidence of the cancers disappeared, the researchers added.

    "A combination of two anti-HER2 therapies -- Tykerb and Herceptin -- induce tumor regression or disappearance in 25 percent of HER2-positive cancers in 11 days," said lead researcher Dr. Nigel Bundred. He is a professor of surgical oncology at the University of Manchester in England.

    Potentially, women who respond to this treatment combination might be able to avoid chemotherapy, he suggested.

    "Instead of chemotherapy for six months and Herceptin for 12 months after surgery, it is likely that therapy and the duration of therapy can be tailored according to early responses," Bundred said.

    However, there are some drawbacks to the treatment. Side effects are common, including heart disease (reported in 5 percent), rashes and diarrhea (about 25 percent), Bundred noted.

    But women who respond to the drug combination will likely need less therapy and have fewer side effects overall, he explained.

    Both drugs are covered by most insurance plans, according to Dr. Eleonora Teplinsky, a medical oncologist with Northwell Health in Lake Success, N.Y.

    The results of the study were scheduled to be presented Thursday at the European Breast Cancer Conference in Amsterdam. Findings presented at meetings are generally viewed as preliminary until they've been published in a peer-reviewed journal.

    About one in five breast cancers is HER2 positive, according to the American Cancer Society (ACS). In these cancers, a gene mutation prompts the growth of cancer cells, and it is generally more aggressive than other types of breast cancer, the ACS says.

    In the first part of this two-part study, Bundred and colleagues randomly assigned 130 women with newly diagnosed, operable HER2-positive cancer to either Herceptin or Tykerb or neither of the drugs in the 11 days before surgery.

    Today on WebMD

    Breast Cancer Overview
    From mammograms to living after treatment.
    Dealing with breast cancer
    Get answers to your questions.
    woman having mammogram
    The 3 latest tips to know.
    woman undergoing breast cancer test
    Most abnormalities aren’t breast cancer.
    Resolved To Quit Smoking
    Breast Cancer Treatments Improving
    Woman getting mammogram
    Screening Tests for Women
    serious woman
    Pink badge on woman chest to support breat cancer
    what is your cancer risk
    breast cancer survivors